These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 29937236)

  • 21. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.
    Groselj U; Kovac J; Sustar U; Mlinaric M; Fras Z; Podkrajsek KT; Battelino T
    Atherosclerosis; 2018 Oct; 277():383-391. PubMed ID: 30270075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
    Descamps OS; Van Caenegem O; Hermans MP; Balligand JL; Beauloye C; Bondue A; Carlier S; Castermans E; Chenot F; Claeys M; De Block C; de Leener A; De Meester A; Demeure F; De Raedt H; Desmet W; Elegeert I; Guillaume M; Hoffer E; Kacenelenbogen R; Lancellotti P; Langlois M; Leone A; Mertens A; Paquot N; Vanakker O; Vanoverschelde JL; Verhaegen A; Vermeersch P; Wallemacq C; Rietzschel E;
    Atherosclerosis; 2018 Oct; 277():369-376. PubMed ID: 30270073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.
    Brett T; Qureshi N; Gidding S; Watts GF
    Atherosclerosis; 2018 Oct; 277():399-406. PubMed ID: 30270077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
    Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
    Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands.
    Jacobs MS; Kaasenbrood F; Postma MJ; van Hulst M; Tieleman RG
    Europace; 2018 Jan; 20(1):12-18. PubMed ID: 27733465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
    Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
    Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk.
    Fairbairn TA; Meads DM; Hulme C; Mather AN; Plein S; Blackman DJ; Greenwood JP
    Heart; 2013 Jul; 99(13):914-20. PubMed ID: 23696198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parent-child genetic testing for familial hypercholesterolaemia in an Australian context.
    Pang J; Martin AC; Bates TR; Hooper AJ; Bell DA; Burnett JR; Norman R; Watts GF
    J Paediatr Child Health; 2018 Jul; 54(7):741-747. PubMed ID: 29626384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia.
    Lázaro P; Pérez de Isla L; Watts GF; Alonso R; Norman R; Muñiz O; Fuentes F; Mata N; López-Miranda J; González-Juanatey JR; Díaz-Díaz JL; Blasco AJ; Mata P
    J Clin Lipidol; 2017; 11(1):260-271. PubMed ID: 28391894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishing a national screening programme for familial hypercholesterolaemia in Lithuania.
    Petrulioniene Z; Gargalskaite U; Kutkiene S; Staigyte J; Cerkauskiene R; Laucevicius A
    Atherosclerosis; 2018 Oct; 277():407-412. PubMed ID: 30270078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.
    Jahn B; Santamaria J; Dieplinger H; Binder CJ; Ebenbichler C; Scholl-Bürgi S; Conrads-Frank A; Rochau U; Kühne F; Stojkov I; Todorovic J; James L; Siebert U
    Atherosclerosis; 2022 Aug; 355():15-29. PubMed ID: 35870306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis.
    Hur C; Choi SE; Kong CY; Wang GQ; Xu H; Polydorides AD; Xue LY; Perzan KE; Tramontano AC; Richards-Kortum RR; Anandasabapathy S
    World J Gastroenterol; 2015 May; 21(18):5513-23. PubMed ID: 25987774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
    JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integration of child-parent screening and cascade testing for familial hypercholesterolaemia.
    Wald DS; Wald NJ
    J Med Screen; 2019 Jun; 26(2):71-75. PubMed ID: 30319009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
    Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
    Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Unim B; Pitini E; De Vito C; D'Andrea E; Marzuillo C; Villari P
    Value Health; 2020 Jan; 23(1):114-126. PubMed ID: 31952666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening individuals with intracranial aneurysms for abdominal aortic aneurysms is cost-effective based on estimated coprevalence.
    Ball BZ; Jiang B; Mehndiratta P; Stukenborg GJ; Upchurch GR; Meschia JF; Worrall BB; Southerland AM
    J Vasc Surg; 2016 Sep; 64(3):811-818.e3. PubMed ID: 27565600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.